Clinical Trial: A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT06948422) titled 'A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)' on April 21.

Brief Summary: The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Hypertension

Intervention: DRUG: Orforglipron

Administered orally.

DRUG: Placebo

Administered orally.

Recruit...